ArticleInternational journal of clinical and experimental pathology2014
Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 7 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Prognostic value of micro-RNA in ovarian cancer: a systematic review and meta-analysis.Frontiers in oncology · 2025Pooled it
- Circulating microRNAs as novel potential diagnostic biomarkers for ovarian cancer: a systematic review and updated meta-analysis.Journal of ovarian research · 2019Pooled it
- MicroRNA-200 and microRNA-30 family as prognostic molecular signatures in ovarian cancer: A meta-analysis.Medicine · 2018Pooled it
- Correlation between miR-200 Family Overexpression and Cancer Prognosis.Disease markers · 2018Pooled it
- Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis.BioMed research international · 2017Pooled it
- Prognostic Role of MicroRNA-200c-141 Cluster in Various Human Solid Malignant Neoplasms.Disease markers · 2015Pooled it
- Prognostic Value and Clinicopathology Significance of MicroRNA-200c Expression in Cancer: A Meta-Analysis.PloS one · 2015Pooled it
- Long Non-Coding, Micro, and Circular RNAs in Ovarian Cancer Metastasis: Pathways and Treatment Approaches.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- Role of DNA methylation and non‑coding RNAs expression in pathogenesis, detection, prognosis, and therapy‑resistant ovarian carcinoma (Review).Molecular medicine reports · 2025Review
- Exploring miRNA profile associated with cisplatin resistance in ovarian cancer cells.Biochemistry and biophysics reports · 2025Article
- Overexpression of miR-200s inhibits proliferation and invasion while increasing apoptosis in murine ovarian cancer cells.PloS one · 2024Article
- Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool.Frontiers in molecular biosciences · 2024Review
- circDENND4C, a novel serum marker for epithelial ovarian cancer, acts as a tumor suppressor by downregulating miR-200b/c.Annals of medicine · 2023Article
- Associations of leptin receptors and miRNA polymorphisms with susceptibility to hypertension.Biomedical reports · 2023Article
- Extracellular urinary microRNAs as non-invasive biomarkers of endometrial and ovarian cancer.Journal of cancer research and clinical oncology · 2023Review
- Genetic associations between miR‑200bT>C and miR‑495A>C polymorphisms and hypertension susceptibility.Experimental and therapeutic medicine · 2023Article
- MicroRNAs as Potential Biomarkers in Gynecological Cancers.Biomedicines · 2023Review
- Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis.Molecular cancer · 2023Article
- Multi-omics analysis of the Indian ovarian cancer cohort revealed histotype-specific mutation and gene expression patterns.Frontiers in genetics · 2023Article
- Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate the association of the expression of members in the miR-200 family with clinicopathological characteristics and their impacts on overall survival in patients with epithelial ovarian cancer (EOC). Expression levels of members in the miR-200 family, including miR-200a, miR-200b, miR-200c, miR-141, and miR-429, were detected by using miRNA qRT-PCR and in situ hybridization. Associations of their expression with clinicopathological factors and overall survival were statistically evaluated. Among five members in the miR-200 family, the expression levels of miR-200a, miR-200b and miR-200c were significantly higher in EOC tissues than those in normal surface ovarian epithelium tissues, in line with the findings ofin situ hybridization analysis. In addition, tumors with high miR-200a and miR-200 bexpressionwere both more likely to have advanced stage (both P=0.006) and higher grade (P=0.01 and 0.02), whilehighmiR-200 cexpression was onlysignificantly associated with advanced stage disease (P=0.01). Moreover, univariate analysis showed that the patients with high miR-200a, miR-200b and miR-200c expression all correlated with shorter overall survival in EOC patients (all P<0.001). Multivariate statistical analysis further identified miR-200a, miR-200b and miR-200c asindependent prognostic factorsfor EOC (all P=0.01). In conclusion, these findings suggest that miR-200a, miR-200b and miR-200c overexpression may promote the aggressive tumor progression and be recognized as reliable markers to predict the survival in patients with EOCs. The three miRNAs could be attractive therapeutic targets in patients with advanced-stage EOCs.
Indexed as
Identifiers
24966949PMC4069884W350383138What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.